AbbVie announced a $1.4 billion investment to build a 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, marking its largest capital investment in a single site. The campus will support production of immunology, neuroscience, and oncology medicines using advanced manufacturing and AI technologies. Construction starts in 2026 and is expected to finish by the end of 2028, creating 734 jobs and over 2,000 construction roles. This project is part of AbbVie's $100 billion U.S. commitment to research, development, and manufacturing over the next decade, enhancing its manufacturing footprint and supporting future medical innovations.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
